股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國衛生集團有限公司 ( 以 CHG HS Limited 名稱在香港經營業務) ( 於百慕達註冊成立之有限公司) 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00673 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 HKD | | 0.1 | HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 100,000,000,000 HKD | ...

China Health Group Limited 中國衛生集團有限公司 (Carrying on business in Hong Kong as CHG HS Limited) (Incorporated in Bermuda with limited liability) （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） （Stock Code 股份代號：673） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, China Health Group Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's w ...

China Health Group Limited 中國衛生集團有限公司 (Carrying on business in Hong Kong as CHG HS Limited) (Incorporated in Bermuda with limited liability) （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） （Stock Code 股份代號：673） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, China Health Group Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's w ...

中國衛生集團有限公司 2025年中期報告 公司資料 董事 執行董事 曹旭先生 鍾浩先生 應任斯女士 非執行董事 應偉先生 黃連海先生 獨立非執行董事 李宏義先生 吳暉先生 楊惠敏女士 公司秘書 徐兆鴻先生 註冊辦事處 Clarendon House 2 Church Street Hamilton HM 11 Bermuda 總辦事處及主要營業地點 香港 中環德輔道中141號 中保集團大廈 8樓801室 主要往來銀行 中國建設銀行(亞洲)股份有限公司 香港 中環干諾道中3號 中國建設銀行大廈28樓 核數師 北京興華鼎豐會計師事務所有限公司 執業會計師 註冊公眾利益實體核數師 香港 觀塘 駿業街46號 廣域創科中心1樓 法律顧問 李偉斌律師行 香港 中環 環球大廈 22樓 主要股份過戶登記處 Appleby Global Corporate Services (Bermuda) Limited Canon's Court, 22 Victoria Street, PO Box HM 1179, Hamilton HM EX Bermuda 香港股份過戶登記分處 卓佳證券登記有限公司 香港 夏慤道16號 遠東金融 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國衛生集團有限公司 ( 以 CHG HS Limited 名稱在香港經營業務) ( 於百慕達註冊成立之有限公司) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00673 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 HKD | | 0.1 | HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 100,000,000,000 HKD ...

Group 1 - The core viewpoint of the article is that China Health Group (00673) reported its interim results for the six months ending September 30, 2025, showing a revenue of HKD 19.61 million, which represents a year-on-year increase of 4.98% [1] - The company reported a loss attributable to shareholders of HKD 10.36 million, which is a reduction of approximately 40.40% compared to the previous year [1] - The basic loss per share is HKD 0.0211 [1]

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 19,610,000, an increase of 4.96% compared to HKD 18,680,000 for the same period in 2024[4] - Gross profit decreased to HKD 1,847,000 from HKD 1,993,000, representing a decline of 7.33%[4] - The net loss for the period was HKD 10,839,000, an improvement from a net loss of HKD 17,624,000 in the previous year, indicating a reduction of 38.55%[5] - The total comprehensive loss for the period was HKD 10,648,000, compared to HKD 18,130,000 in the previous year, indicating a decrease of 41.06%[5] - The group reported a total loss of HKD 10,363,000 for the period, compared to a loss of HKD 17,387,000 in the previous period, indicating an improvement of approximately 40.5%[16] - The company reported a loss attributable to owners of HKD 10,363,000 in 2025, compared to a loss of HKD 17,387,000 in 2024, indicating a reduction in losses by 40.3%[30] Cash Flow and Assets - Operating cash flow improved significantly to HKD 2,397,000 from a cash outflow of HKD 11,538,000 in the prior period[9] - Financing activities generated a net cash inflow of HKD 59,682,000, compared to HKD 9,768,000 in the previous year, showing a substantial increase[9] - Total current assets increased to HKD 169,308,000 from HKD 114,620,000, reflecting a growth of 47.73%[6] - The total assets of the group as of September 30, 2025, amounted to HKD 201,466,000, an increase from HKD 147,348,000 as of March 31, 2025[18] - The total liabilities of the group as of September 30, 2025, were HKD 211,969,000, up from HKD 147,253,000 as of March 31, 2025[18] - The group's cash and cash equivalents amounted to approximately HKD 63 million, a significant increase from HKD 1 million as of March 31, 2025[91] Revenue Breakdown - The distribution of revenue from external customers in China was HKD 19,610,000 for the six months ended September 30, 2025, compared to HKD 18,680,000 in the previous year, reflecting a growth of approximately 4.95%[21] - Revenue from medical device and consumables distribution and services increased to HKD 15,551,000 in 2025 from HKD 13,209,000 in 2024, representing a growth of 17.7%[22] - Revenue from hospital operation and management services decreased to HKD 4,059,000 in 2025 from HKD 5,471,000 in 2024, a decline of 25.8%[22] - Total revenue for the period reached HKD 19,610,000 in 2025, up from HKD 18,680,000 in 2024, marking an increase of 4.9%[22] Liabilities and Provisions - Current liabilities rose to HKD 211,762,000 from HKD 131,965,000, an increase of 60.25%[6] - The company has recognized a provision of $4,000,000 (approximately HKD 31,120,000) in its profit and loss statement for the year ending March 31, 2025[45] - The company is actively pursuing repayment of outstanding loans, with a total of approximately RMB 59,100,000 (around HKD 64,800,000) in unpaid principal and interest from Shuangluan Hospital[66] Operational Developments - The company plans to launch new cardiovascular products, including pacemakers, in the second half of the fiscal year ending March 31, 2026[56] - The company has strategically adjusted its product portfolio to focus on high-margin products and expand into new surgical fields[56] - The hospital plans to shift its focus from capital-intensive surgical services to rehabilitation and nursing services, aiming to improve asset efficiency and align with national healthcare policies[60] - A new hospital director has been appointed to oversee the transition to a health management-centered model, with plans to hire more qualified medical personnel[64] Shareholder and Equity Matters - The company has issued 100,000,000 shares as of March 31, 2025, with paid-up capital of HKD 49,164,000[46] - The group’s total equity attributable to owners decreased to HKD 51,419,000 as of September 30, 2025, from HKD 59,753,000 as of April 1, 2024[10] - No interim dividend has been recommended for shareholders for the current period[96] Legal and Settlement Issues - The company has been involved in litigation regarding the $4,000,000 loan note, with the latest court ruling rejecting claims from Capital Foresight[44] - The court ruled that the statutory demand was an abuse of process and ordered the return of the $4,000,000 to the company[39] - The company entered into a settlement agreement involving the acquisition of Tsun Mei Group, which includes a payment of HKD 12,000,000[47] Employee and Management Changes - The total employee cost, including directors' remuneration, was approximately HKD 8.2 million, up from HKD 6.8 million in the previous period[94] - The group employed 127 employees as of September 30, 2025, down from 148 employees as of March 31, 2025[94] Future Outlook - The group aims to enhance its existing business and management team in the second half of the year, with expectations of improved operational performance compared to the previous year[95] - The company is in discussions with two leading cardiovascular hospitals in Beijing to introduce new cardiovascular products, expected to enhance revenue sources[57]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） 有關截至二零二五年三月三十一日止年度之年報 所載持續經營的不發表意見的最新情況 中國衛生集團有限公司（「本公司」）董事會謹此更新其解決核數師對本公司截至二零二五年三月 三十一日止年度綜合財務報表有關持續經營不發表意見（「不發表意見」）的行動。 茲提述本公司截至二零二五年三月三十一日止年度之年報（「年報」）。除非文義另有所指，本公佈 所用詞彙與年報內所界定者具有相同涵義。 誠如年報所載，為解決截至二零二六年三月三十一日止年度本集團之流動資金壓力及不發 表意見，董事會積極實施多項計劃及措施，包括(i)訂立認購協議以籌集估計所得款項總額約 70,000,000港元；(ii)建議供股以籌集估計所得款項總額約15,000,000港元；( ...

格隆汇11月18日丨中国卫生集团(00673.HK)公告，董事会会议将于2025年11月28日举行，以便考虑及批 准(其中包括)公司及其附属公司截至2025年9月30日止6个月未经审核中期业绩。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因依賴該等 內容而引致之任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） 董事會會議日期 承董事會命 中國衛生集團有限公司 董事會主席兼執行董事 曹旭 香港，二零二五年十一月十八日 於本公佈日期，董事會包括三名執行董事曹旭先生（主席）、鍾浩先生及應任斯女士；兩名非執行 董事應偉先生及黃連海先生；及三名獨立非執行董事李宏義先生、吳暉先生及楊惠敏女士。 中國衛生集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於二零二五年十一 月二十八日舉行，以便考慮及批准（其中包括）本公司及其附屬公司截至二零二五年九月三十日止 六個月之未經審核中期業績。 ...